3 completed, 1 unknown. 2 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow regdanvimab: new trials by email Literature Review of regdanvimab trials Research Report on regdanvimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19 tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab - Coronavirus Infections | Phase 4 | Unknown | City Clinical Hospital No.52 of Moscow Healthcare Department | 82 | 2022-08-18 | 2023-08-08 |
| A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection CT-P59, Placebo - SARS-CoV-2 Infection | Phase 2 / Phase 3 | Completed | Celltrion | 1642 | 2020-10-05 | 2022-07-20 |
| This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) CT-P59 - SARS-CoV-2 Infection | Phase 1 | Completed | Celltrion | 18 | 2020-09-04 | 2022-04-08 |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects CT-P59, Placebo - SARS-CoV-2 Infection | Phase 1 | Completed | Celltrion | 32 | 2020-07-18 | 2021-11-16 |
COVID-19 (3) · Coronavirus Infections (1)
Celltrion (3) · City Clinical Hospital No.52 of Moscow Healthcare Department (1)
South Korea (3) · Russia (1)
PMID 34473343, PMID 34551869, PMID 35713300, PMID 35295819, PMID 36043180, PMID 37928549